Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

The impact of prophylactic oral ganciclovir therapy on the incidence of cytomegalovirus (CMV) disease, patient and graft survival, and costs in patients receiving kidney and liver transplants is ...

More than 55% of transplant recipients with refractory CMV infections achieved confirmed ... locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR ...

We wanted to find out if pre-emptive treatment aimed at transplant recipients who are at risk of developing CMV disease, rather than administering universal prophylaxis, including those who are ...

CMV is one of the most common and serious post-transplant infections with an estimated incidence rate of between 16% and 56% in solid organ transplants, and 30% to 70% in HSCT procedures.